Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Respiratory syncytial virus G protein is a protein produced by the respiratory syncytial virus. The Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) pipeline drugs market research report provides comprehensive information on the Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also reviews key players involved in Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) targeted therapeutics development with respective active and dormant or discontinued projects.

RSV G Pipeline Drugs Market Segmentation by Therapy Areas

The key therapy area of the RSV G pipeline drugs market is infectious disease.

RSV G Pipeline Drugs Market Segmentation by Mechanisms of Action

The key mechanisms of action of the RSV G pipeline drugs market are Respiratory Syncytial Virus Attachment Glycoprotein Inhibitor and Respiratory Syncytial Virus Fusion Protein Inhibitor. Respiratory Syncytial Virus Attachment Glycoprotein Inhibitor leads the pipeline market.

RSV G Pipeline Drugs Market Analysis, by Mechanisms of Action

RSV G Pipeline Drugs Market Analysis, by Mechanisms of Action

For more RSV G pipeline drugs market mechanisms of action insights, download a free report sample

RSV G Pipeline Drugs Market Segmentation by Routes of Administration

The key routes of administration in the RSV G pipeline drugs market are intramuscular and nasal.

RSV G Pipeline Drugs Market Analysis, by Routes of Administration

RSV G Pipeline Drugs Market Analysis, by Routes of AdministrationFor more RSV G pipeline drugs market routes of administration insights, download a free report sample

RSV G Pipeline Drugs Market Segmentation by Molecule Types

The key molecule types in the RSV G pipeline drugs market are monoclonal antibody, recombinant vector vaccine, and subunit vaccine. Monoclonal antibody leads the pipeline market.

RSV G Pipeline Drugs Market Analysis, by Molecule Types

RSV G Pipeline Drugs Market Analysis, by Molecule Types

To know more about the molecule types in the RSV G pipeline drugs market, download a free report sample

RSV G Pipeline Drugs Market - Competitive Landscape

The leading companies in the RSV G pipeline drugs market are AstraZeneca Plc, Bavarian Nordic AS, IDBiologics Inc, Sigmovir Biosystems Inc, and Visterra Inc. Bavarian Nordic AS dominates the market in 2022.

RSV G Pipeline Drugs Market Analysis, by Companies

RSV G Pipeline Drugs Market Analysis, by Companies

To know more about the companies in the RSV G pipeline drugs market, download a free report sample

RSV G Pipeline Drugs Market Report Overview

Key Therapy Area Infectious Disease
Key Mechanisms of Action Respiratory Syncytial Virus Attachment Glycoprotein Inhibitor and Respiratory Syncytial Virus Fusion Protein Inhibitor
Key Routes of Administration Intramuscular and Nasal
Key Molecule Types Monoclonal Antibody, Recombinant Vector Vaccine, and Subunit Vaccine
Leading Companies AstraZeneca Plc, Bavarian Nordic AS, IDBiologics Inc, Sigmovir Biosystems Inc, and Visterra Inc

Scope

  • The report provides a snapshot of the global therapeutic landscape for Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G)
  • The report reviews Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration to discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA), and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews the latest news and deals related to Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) targeted therapeutics

Reasons to Buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies.
  • Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage.
  • Identify and understand the targeted therapy areas and indications for Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G). Identify the use of drugs for target identification and drug repurposing.
  • Identify potential new clients or partners in the target demographic.
  • Develop strategic initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions effectively by identifying key players and their most promising pipeline therapeutics.
  • Devise corrective measures for pipeline projects by understanding Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) development landscape.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

AstraZeneca Plc
Bavarian Nordic AS
IDBiologics Inc
Sigmovir Biosystems Inc
Visterra Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) – Overview

Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) – Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) – Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) – Companies Involved in Therapeutics Development

AstraZeneca Plc

Bavarian Nordic AS

IDBiologics Inc

Sigmovir Biosystems Inc

Visterra Inc

Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) – Drug Profiles

MVA-BN RSV – Drug Profile

Product Description

Mechanism Of Action

History of Events

respiratory syncytial virus (virus like particle) vaccine – Drug Profile

Product Description

Mechanism Of Action

History of Events

RSV – Drug Profile

Product Description

Mechanism Of Action

History of Events

TRL-3D3 – Drug Profile

Product Description

Mechanism Of Action

History of Events

VIS-RSV – Drug Profile

Product Description

Mechanism Of Action

History of Events

Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) – Dormant Products

Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) – Product Development Milestones

Featured News & Press Releases

Nov 14, 2022: Chinese CDE grants IND clearance for Nuance’s RSV vaccine trial

Jun 28, 2022: Bavarian Nordic announces grant of PRIME eligibility from the European Medicines Agency for its RSV vaccine candidate for the prevention of respiratory syncytial virus in older adults

Apr 20, 2022: Bavarian Nordic announces initiation of a global phase 3 clinical trial of its RSV vaccine candidate in older adults

Feb 22, 2022: Open Orphan : FDA breakthrough designation for Big Pharma RSV candidate

Feb 14, 2022: Bavarian Nordic announces Breakthrough Therapy Designation for its RSV vaccine candidate for the prevention of respiratory syncytial virus in older adults

Dec 06, 2021: Bavarian Nordic commits to initiating phase 3 trial of RSV vaccine candidate and to strengthening its capital base

Sep 07, 2021: Open Orphan: Positive results from RSV Human Challenge Study

Sep 01, 2021: Bavarian Nordic reports positive results from human challenge trial of its RSV vaccine candidate

Aug 08, 2018: Bavarian Nordic Announces Positive Data from Phase 2 Extension Study of its Universal RSV Vaccine

Mar 06, 2018: Bavarian Nordic Announces Additional Positive Data from a Phase 2 Study of its Universal RSV Vaccine

Nov 09, 2017: Bavarian Nordic Announces Initiation of Phase 2 Booster Study of its Universal RSV Vaccine

Sep 21, 2017: Bavarian Nordic Provides Update on its Universal RSV Vaccine

Jun 27, 2017: Bavarian Nordic Announces Positive Data from Ongoing Phase 2 Study Investigating a Universal RSV Vaccine

Feb 23, 2017: Updated Phase 1 Data Show Bavarian Nordic’s Vaccine Candidate Induces a Broad and Durable Immune Response against RSV

Dec 14, 2016: Bavarian Nordic Announces Completion of Enrollment for Phase 2 Clinical Trial of RSV Vaccine

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Indication, 2022

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Pipeline by AstraZeneca Plc, 2022

Pipeline by Bavarian Nordic AS, 2022

Pipeline by IDBiologics Inc, 2022

Pipeline by Sigmovir Biosystems Inc, 2022

Pipeline by Visterra Inc, 2022

Dormant Projects, 2022

Figures

List of Figures

Number of Products under Development by Stage of Development, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

Frequently asked questions

Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update standard reports
Currency USD
$3,500

Can be used by individual purchaser only

$10,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Pharmaceuticals
New
Pharma M&A Deals Q1 2024 - Top Themes - Thematic…
$995 | May 2024
Pharmaceuticals
New
Future of Pharma - Looking Ahead to 2024
$495 | May 2024
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.